Impact of Fluoroquinolone Use on Mortality Among a Cohort of Patients With Suspected Drug-Resistant Tuberculosis | Zendy

Marva Seifert | Zendy; Sophia B. Georghiou | Zendy; Richard S. Garfein | Zendy; Donald G. Catanzaro | Zendy; Timothy C. Rodwell | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Impact of Fluoroquinolone Use on Mortality Among a Cohort of Patients With Suspected Drug-Resistant Tuberculosis

Author(s) -

Marva Seifert,

Sophia B. Georghiou,

Richard S. Garfein,

Donald G. Catanzaro,

Timothy C. Rodwell

Publication year - 2017

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cix422

Subject(s) - medicine , tuberculosis , cohort , drug , cohort study , drug resistant tuberculosis , drug resistance , intensive care medicine , mycobacterium tuberculosis , pharmacology , microbiology and biotechnology , pathology , biology

Previous retrospective and in vitro studies suggest that use of later-generation fluoroquinolones may reduce mortality risk and improve treatment outcomes for drug-resistant tuberculosis (TB) patients, including individuals resistant to a fluoroquinolone. Meta-analysis results are mixed and few studies have examined this relationship prospectively.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research